ABVC BioPharma announces CFO resignation, CEO steps in as interim

ABVC BioPharma, Inc. (NASDAQ:ABVC), a pharmaceutical company based in Fremont, California, with a market capitalization of $7.79 million, disclosed the departure of its Chief Financial Officer (CFO), Mr. Leeds Chow, on March 5, 2025. According to the 8-K filing with the Securities and Exchange Commission, Mr. Chow has resigned from his role, prompting the company to initiate a search for a new CFO. InvestingPro analysis indicates the company currently maintains a FAIR financial health score of 2.18.

In the interim, ABVC BioPharma’s Chief Executive Officer (CEO), Uttam Patil, will assume the additional responsibilities of CFO. The company has not provided specific reasons for Mr. Chow’s resignation but has confirmed that the transition is effective immediately. The leadership change comes as the company faces challenging market conditions, with revenue declining by 31% in the last twelve months.

ABVC BioPharma, previously known as American BriVision (Holding) Corp, operates within the pharmaceutical preparations sector under the industrial classification code 2834. The firm is incorporated in Nevada and has its executive offices located at 44370 Old Warm Springs Blvd., Fremont, CA 94538.

The company’s common stock is traded on The Nasdaq Stock Market under the ticker symbol ABVC. Currently trading at $0.64, the stock has shown mixed performance with a 7.85% gain year-to-date but a significant decline of 49.1% over the past year. According to InvestingPro analysis, the stock appears undervalued based on its Fair Value calculation. As of the date of the report, ABVC BioPharma has not indicated any changes to its business operations or strategic direction in light of the CFO’s departure. The company is scheduled to report its next earnings on March 14, 2025.

This announcement is based on the most recent 8-K filing from ABVC BioPharma with the SEC and reflects the company’s current administrative changes. Investors and stakeholders are advised to follow official releases from ABVC BioPharma for further updates regarding the appointment of a new CFO.

This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.